Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its ...

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

In a report released today, Matt Miksic from Barclays maintained a Buy rating on Globus Medical (GMED – Research Report), with a price target ...

Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share.

Globus Medical (GMED) has agreed to buy Nevro (NVRO) through an all-cash deal valued at around $250M. Read more here.

Globus Medical expects the Nevro acquisition to be accretive to its earnings in the second year of operation. Globus Medical expects to report full financial results for 2024 and provide its updated ...

Globus Medical and Nevro Preliminary Full-Year 2024 Revenue Outlook: On January 8, 2025, Globus Medical announced preliminary 2024 net sales of $2.52 billion, an increase of 60.6% over prior year ...

Audubon-based Globus Medical has announced its acquisition of California life sciences company Nevro Corp. for $250 million ...

Globus Medical has a 12 month low of $49.33 and a 12 month high of $94.93. Globus Medical ( NYSE:GMED – Get Free Report ) last issued its quarterly earnings data on Tuesday, November 5th.